Emerging Therapeutics for the Prevention of Chemotherapy-Induced Cardiotoxicity: Advances and Future Perspectives
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 1509
Special Issue Editors
Interests: interventional cardiology; antiplatelet therapy; cardio-oncology; gender medicine; research methodology; drug
Special Issues, Collections and Topics in MDPI journals
Interests: cardio-oncology; ischemic heart disease; biomarkers; cardiovascular therapies
Interests: cardio-oncology; ischemic heart disease; precision medicine; molecular pharmacology
Interests: cardio-oncology; inflammation; chemoresistance; radioresistance; nanotechnology; endocrine disruptor
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chemotherapy-induced cardiotoxicity (CIC) is a major concern in oncology and cardiovascular medicine, as it poses a significant barrier to effective cancer treatment and long-term patient survival. The growing population of cancer survivors necessitates novel strategies to mitigate cardiotoxic effects without compromising oncological outcomes. This Special Issue—Emerging Therapeutics for the Prevention of Chemotherapy-Induced Cardiotoxicity: Advances and Future Perspectives—seeks to address this pressing need by bringing together cutting-edge research and reviews on pharmacological innovations and prevention protocols.
We aim to gather contributions on the latest protective agents, including established cardioprotective drugs and novel molecular entities. Submissions focusing on the repurposing of existing cardiovascular drugs for CIC prevention, early detection biomarkers, and the role of multidisciplinary cardio-oncology care pathways are highly encouraged. In addition, we welcome studies on molecular mechanisms that elucidate cardiotoxic pathways and clinical trials evaluating novel therapeutic approaches.
This Special Issue will provide clinicians and researchers with a comprehensive understanding of CIC and will outline future directions for preventive strategies. By fostering collaborations across disciplines, we hope to advance the development of tailored interventions that improve the quality of life and cardiac outcomes in cancer patients.
Dr. Luigi Spadafora
Dr. Marco Bernardi
Dr. Sarto Sarto
Dr. Vincenzo Quagliariello
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardio-oncology
- chemotherapy-induced cardiotoxicity
- cardioprotective agents
- biomarkers
- heart failure prevention
- precision medicine
- pharmacological innovation
- molecular targets
- cancer survivorship
- multidisciplinary care
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
